These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9239804)

  • 1. Plasma and saliva concentrations of rifampicin in man after oral administration.
    Orisakwe OE; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):45-9. PubMed ID: 9239804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of rifampicin following intranasal and oral administration.
    Mamidi NV; Prabhakar MC; Krishna DR
    Indian J Lepr; 1996; 68(2):149-53. PubMed ID: 8835583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin.
    Orisakwe OE; Akunyili DN; Agbasi PU; Ezejiofor NA
    Am J Ther; 2004; 11(4):283-7. PubMed ID: 15266220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and urine concentrations of rifampicin administered by intravenous infusion in man.
    Acocella G; Bonollo L; Mainardi M; Margaroli P; Tenconi LT
    Arzneimittelforschung; 1977; 27(6):1221-6. PubMed ID: 578447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlordiazepoxide concentrations in saliva and plasma measured by radioimmunoassay.
    Lucek R; Dixon R
    Res Commun Chem Pathol Pharmacol; 1980 Feb; 27(2):397-400. PubMed ID: 7367755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of two erythromycin esters in plasma and in saliva following oral administration in humans.
    Ducci M; Scalori V; del Tacca M; Soldani G; Bernardini C; Grothe E; Bertelli A
    Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):494-7. PubMed ID: 7298242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
    Park JY; Kim KA; Kang MH; Kim SL; Shin JG
    Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.
    Pargal A; Rani S
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):70-9. PubMed ID: 11263520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin.
    Hartkoorn RC; Khoo S; Back DJ; Tjia JF; Waitt CJ; Chaponda M; Davies G; Ardrey A; Ashleigh S; Ward SA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 857(1):76-82. PubMed ID: 17643357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
    Kelkar MS; Saraf AP; Bakhle DS; Nazare V; Ajay S; Hegde S; Lal HM; Cooverji ND; Bruzzese T
    Int J Clin Pharmacol Res; 1998; 18(3):137-43. PubMed ID: 9825270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of saliva samples for the estimation of dipyrone metabolites pharmacokinetics.
    Caraco Y; Zylber-Katz E; Granit L; Levy M
    Arzneimittelforschung; 1993 Nov; 43(11):1204-8. PubMed ID: 8292065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Skin penetration of sulfamethoxazole and trimethoprim after oral administration].
    Królicki A
    Ann Acad Med Stetin; 2002; 48():59-73. PubMed ID: 14601469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Radioimmunologic determination of the progestagen dienogest in plasma and saliva].
    Hobe G; Klinger G; Reddersen G; Erdmann A; Klinger G
    Pharmazie; 1986 Nov; 41(11):772-4. PubMed ID: 3484359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronopharmacokinetics of rifampicin.
    Avachat MK; Rambhau D; Rao VV; Rao BR; Rao JV
    Indian J Physiol Pharmacol; 1992 Oct; 36(4):251-4. PubMed ID: 1291477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.